Although amyloid burden was not reduced by Ctsb treatment, our proteomics data revealed a downward trend of App and App.Aplp2 protein levels in the AD‐Ctsb group compared to AD‐Con. This evidence concerns the gene APLP2 and Alzheimer disease.